BRIEF-Citius Oncology Announces U.S. Commercial Launch Of Lymphir For Cutaneous T-Cell Lymphoma

Reuters
Yesterday
BRIEF-<a href="https://laohu8.com/S/CTOR">Citius Oncology</a> Announces U.S. Commercial Launch Of Lymphir For Cutaneous T-Cell Lymphoma

Dec 1 (Reuters) - Citius Oncology Inc CTOR.O:

  • CITIUS ONCOLOGY ANNOUNCES U.S. COMMERCIAL LAUNCH OF LYMPHIR™, A NOVEL CANCER IMMUNOTHERAPY FOR CUTANEOUS T-CELL LYMPHOMA (CTCL)

  • CITIUS ONCOLOGY ANNOUNCES U.S. COMMERCIAL LAUNCH OF LYMPHIR™, A NOVEL CANCER IMMUNOTHERAPY FOR CUTANEOUS T-CELL LYMPHOMA (CTCL)

Source text: ID:nPn3zMLYca

Further company coverage: CTOR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10